Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Frazier Life Sciences XII Fund Launch: Frazier Life Sciences has closed its latest fund, Frazier Life Sciences XII, L.P., with over $1.3 billion in capital commitments, focusing on creating and investing in innovative biopharmaceutical companies.
Investment Strategy and Achievements: The firm has raised over $5.3 billion since 2016, launched 25 new companies since 2020, and has a strong track record with over 65 FDA-approved therapeutics and more than 60 IPOs or strategic acquisitions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAMS
Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 48.63 USD with a low forecast of 37.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.440
Low
37.00
Averages
48.63
High
60.00
Current: 31.440
Low
37.00
Averages
48.63
High
60.00
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NAMS Options Analysis: $30 Put Contract Offers Attractive Yield Boost
- Put Option Appeal: The $30.00 put option for NAMS has a current bid of 20 cents, and if an investor sells this contract, they commit to buying shares at $30.00, effectively lowering their cost basis to $29.80, which is about a 6% discount from the current price of $31.77, making it attractive for those looking to enter at a lower price.
- Yield Potential: Should the put option expire worthless, it would yield a 0.67% return on cash commitment, or an annualized yield of 3.86%, referred to as YieldBoost, highlighting the potential profitability of this contract.
- Call Option Returns: The $35.00 call option has a current bid of 40 cents, and if an investor buys shares at $31.77 and sells this call, they could achieve a total return of 11.43% if the stock is called away at expiration, showcasing the potential upside of this strategy.
- Risk Assessment: Current analytics suggest a 65% chance that the $30 put option will expire worthless, while the $35 call option has a 56% chance of doing the same, indicating that investors should carefully weigh the risks and rewards when selecting their options strategies.
Continue Reading
NewAmsterdam Pharma Expects EMA Approval for Obicetrapib in 2H26
- Clinical Trial Progress: NewAmsterdam Pharma has enrolled its first patient in the RUBENS Phase 3 trial initiated in December 2025, which is expected to provide new treatment options for patients with metabolic syndrome, thereby enhancing the company's competitive position in the cardiovascular disease market.
- Strong Financial Position: As of December 31, 2025, NewAmsterdam reported a cash, cash equivalents, and marketable securities balance of approximately $729 million, which is sufficient to fund operations through the anticipated readout of the PREVAIL trial, ensuring future commercialization potential.
- Regulatory Advancements: The company is advancing its EMA applications for obicetrapib and its fixed-dose combination with Menarini, with an expected approval decision in 2H26, which will lay the groundwork for commercialization in the European market.
- Clear Strategic Goals: NewAmsterdam plans to initiate a clinical trial for Alzheimer's disease in 2026, further expanding the indications for obicetrapib, demonstrating the company's strategic positioning in both cardiovascular and neurodegenerative disease sectors.
Continue Reading